EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

• Published in: Obesity facts Vol. 17; no. 4; pp. 374 - 444
• Main Authors: Tacke, Frank, Horn, Paul, Wai-Sun Wong, Vincent, Ratziu, Vlad, Bugianesi, Elisabetta, Francque, Sven, Valenti, Luca, Roden, Michael, Schick, Fritz, Yki-Järvinen, Hannele, Gastaldelli, Amalia, Vettor, Roberto, Gema, Frühbeck, Dicker, Dror
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 2024; Karger Publishers
• Subjects: Agreements; Alcohol use; Cardiometabolic Risk Factors; Clinical medicine; Clinical practice guidelines; Committees; Delphi method; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - therapy; Evidence-based medicine; Fatty liver; Guidelines; Humans; Liver cancer; Liver Cirrhosis - complications; Liver Cirrhosis - therapy; Liver diseases; Liver Neoplasms - etiology; Liver Neoplasms - therapy; Metabolism; Mortality; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - therapy; Obesity - complications; Obesity - therapy; Risk Factors; Systematic review
• ISSN: 1662-4025; 1662-4033; 1662-4033
• DOI: 10.1159/000539371

Summary Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake. The spectrum of MASLD includes steatosis, metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), fibrosis, cirrhosis and MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis and treatment for MASLD. Case-finding strategies for MASLD with liver fibrosis, using non-invasive tests, should be applied in individuals with cardiometabolic risk factors, abnormal liver enzymes, and/or radiological signs of hepatic steatosis, particularly in the presence of type 2 diabetes (T2D) or obesity with additional metabolic risk factor(s). A stepwise approach using blood-based scores (such as FIB-4) and, sequentially, imaging techniques (such as transient elastography) is suitable to rule-out/in advanced fibrosis, which is predictive of liver-related outcomes. In adults with MASLD, lifestyle modification – including weight loss, dietary changes, physical exercise and discouraging alcohol consumption – as well as optimal management of comorbidities – including use of incretin-based therapies (e.g. semaglutide, tirzepatide) for T2D or obesity, if indicated – is advised. Bariatric surgery is also an option in individuals with MASLD and obesity. If locally approved and dependent on the label, adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2) should be considered for a MASH-targeted treatment with resmetirom, which demonstrated histological effectiveness on steatohepatitis and fibrosis with an acceptable safety and tolerability profile. No MASH-targeted pharmacotherapy can currently be recommended for the cirrhotic stage. Management of MASH-related cirrhosis includes adaptations of metabolic drugs, nutritional counselling, surveillance for portal hypertension and HCC, as well as liver transplantation in decompensated cirrhosis.